Loading
A phase 1/2 trial of Bevacizumab, Pembrolizumab and Temozolomide in glioma & glioblastoma, run by TME Pharma AG, active and no longer recruiting.
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients is a phase 1/2 interventional study registered as NCT04121455 by TME Pharma AG, with 117 participants enrolled, started 2019-09-12 and due to reach its primary completion in 2028-12. Interventions recorded: Olaptesed pegol, Radiotherapy, Bevacizumab, Pembrolizumab and Temozolomide (TMZ).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma, Pembrolizumab and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/